Moderna and Merck's Melanoma Vaccine Shows Promising Results in Late-Stage Trial

A major breakthrough in cancer treatment has been announced by Moderna and Merck. The companies have reported positive results from a late-stage trial of their personalized vaccine for melanoma, which is the deadliest form of skin cancer.

The trial involved over 1,100 patients who had undergone surgery to remove their tumors. Those who received the mRNA-based vaccine in combination with Keytruda, an immune drug developed by Merck, were more likely to prevent the cancer's return than those who only received Keytruda.

According to Moderna CEO Stéphane Bancel, the personalized vaccine could be approved as soon as 2027. However, questions remain about the cost and feasibility of producing such bespoke cancer treatments at scale.

The worldwide market for drugs to treat operable melanoma is approximately $2.3 billion per year, according to Bloomberg Intelligence analyst Max Nisen. While some analysts are bullish about the vaccine's potential, others have expressed skepticism, citing concerns about its cost and limited efficacy in treating melanoma alone.